Efficacy and Tolerability of a Combined Moxifloxacin-Dexamethasone Formulation for Topical Prophylaxis in Phacoemulsification: An Open-Label Single-Arm Clinical TrialReport as inadecuate




Efficacy and Tolerability of a Combined Moxifloxacin-Dexamethasone Formulation for Topical Prophylaxis in Phacoemulsification: An Open-Label Single-Arm Clinical Trial - Download this document for free, or read online. Document in PDF available to download.

Journal of OphthalmologyVolume 2011 2011, Article ID 769571, 5 pages

Clinical StudyAmerican Eye Center, Level 5, Shangri-La Plaza, EDSA, Corner Shaw Boulevard, Ortigas Center, Mandaluyong City 1554, Philippines

Received 3 January 2011; Accepted 14 March 2011

Academic Editor: David A. Wilkie

Copyright © 2011 Cesar Ramon G. Espiritu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. The use of a fixed-combination antibiotic corticosteroid for infection prophylaxis in Asian patients undergoing phacoemulsification has not been reported. Methods. A 15-day, open-label, single-arm trial of 64 patients for phacoemulsification with intraocular lens IOL implantation is described. Patients applied moxifloxacin 0.5%-dexamethasone 0.1% Vigadexa eye drops four times daily before and until 15 days after surgery. Anterior chamber AC reaction, visual acuity, ocular pain and signs, and intraocular pressure IOP were assessed at baseline and on postoperative days 1, 3, 8, and 15. Results. At day 15, 55 91.7% patients scored 0 <5 cells in AC reaction. No surgery-related infection occurred. Mean best-corrected visual acuity improved 0.5 logMAR from baseline to 0.0 logMAR . Mean IOP remained at 12-13 mm Hg over the 15-daytreatment. Only 2 patients 3.1% reported minimum ocularpain. Two 3.1% patients were shifted to prednisolone acetatefor severe inflammation. At the end of the study period, 8.3%were given fluorometholone for 1 week for AC reaction grade>0. No drug-related adverse event was reported. Conclusion. Following phacoemulsification and IOLimplantation, the topical combination moxifloxacin0.5%-dexamethasone 0.1% was effective in preventinginfection and controlling inflammation and was welltolerated.





Author: Cesar Ramon G. Espiritu, Mary Ellen A. Sy, and Tommee Lynne G. Tayengco

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents